Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00822926 · ClinicalTrials.gov registry record · NA
Subcutaneous Botulinum Toxin for Cutaneous Allodynia - Enriched Responder Trial
A NA study, sponsored by Stanford University.
- Terminated
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT00822926: Clinical Trial NA study, sponsored by Stanford University.
NCT00822926 is a NA study that was terminated before completion, run by Stanford University. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00822926, a NA study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
Superficial injection of Botulinum toxin has been advocated for cosmetic purposes but has also been reported to be helpful for some pain conditions. The investigators have observed prolonged profound analgesia following subcutaneous superficial injection of Botulinum Toxin Type A (BTA) in patients with certain types of neuropathic pain. the investigators propose to study if addition of BTA extends pain relief compared to placebo when injected subcutaneously into areas of cutaneous allodynia (the property that a normally non-noxious stimulus is perceived as painful).
Interventions
- DRUG Saline
- DRUG Botulinum Toxin Type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2009-01 |
| Est. Completion | 2013-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00822926
The ClinicalTrials.gov registry entry for NCT00822926 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT00822926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00822926 about?
NCT00822926 is a clinical study titled "Subcutaneous Botulinum Toxin for Cutaneous Allodynia - Enriched Responder Trial". Superficial injection of Botulinum toxin has been advocated for cosmetic purposes but has also been reported to be helpful for some pain conditions. The investigators have observed prolonged profound analgesia following subcutaneous superficial injection of Botulinum Toxin Type A (BTA) in patients w...
What is the current status of trial NCT00822926?
This trial is currently terminated. It is a NA study. The enrollment target is 5 participants. The study started on 2009-01. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00822926?
The interventions under investigation include: Saline (DRUG), Botulinum Toxin Type A (DRUG).
Who is sponsoring clinical trial NCT00822926?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.